| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -16.76% | -159.26% | -902.50% | — | -2121.65% | -81.89% | -643.44% | -626.42% | -579.08% | — | — | — |
| EBITDA Margin | -16.58% | -158.80% | -896.22% | — | -2114.20% | -81.01% | -640.35% | -622.08% | -576.65% | — | — | — |
| Net Margin | -8.47% | -140.87% | -854.78% | — | -2076.35% | -78.57% | -611.63% | -613.02% | -474.65% | — | — | — |
| Current Ratio | 5.22 | 2.42 | 3.41 | 5.95 | 9.59 | 9.19 | 11.57 | 12.05 | 9.13 | 7.52 | 20.09 | 27.72 |
| Quick Ratio | 5.22 | 2.42 | 3.41 | 5.95 | 9.59 | 9.19 | 11.57 | 12.05 | 9.13 | 7.52 | 20.09 | 27.72 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -2.96% | -120.44% | -148.98% | -112.61% | -76.87% | -25.83% | -35.73% | -43.08% | -37.84% | -55.41% | -23.96% | -40.62% |
| ROA | -2.38% | -33.71% | -44.75% | -91.45% | -67.97% | -21.94% | -28.72% | -33.86% | -25.29% | -45.11% | -21.27% | -33.40% |
| Asset Turnover | 0.28 | 0.24 | 0.05 | 0.00 | 0.03 | 0.28 | 0.05 | 0.06 | 0.05 | 0.00 | — | — |
| Book Value / Share | 18.44 | 5.56 | 8.98 | 1.71 | 3.90 | 6.79 | 10.40 | 9.24 | 6.37 | 4.64 | — | — |
Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics for serious viral diseases worldwide. Its pipeline features long-acting helicase-primase inhibitors ABI-5366 and ABI-1179, currently in Phase 1a/1b clinical studies targeting recurrent genital herpes caused by herpes simplex virus. The company is also advancing ABI-4334, a next-generation capsid assembly modulator in Phase 1b trials designed to disrupt the hepatitis B virus replication cycle, and ABI-6250, an oral hepatitis delta virus entry inhibitor in Phase 1a studies. Additional candidates include ABI-7272, a broad-spectrum non-nucleoside polymerase inhibitor for transplant-related herpesviruses. Assembly Biosciences Inc. leverages expertise in virology to create innovative oral therapies aimed at improving treatment outcomes for patients with chronic viral infections like hepatitis B and delta, as well as herpesviruses. Founded in 2005 and headquartered in South San Francisco, California, the company plays a key role in the biotechnology sector by addressing unmet needs in antiviral drug development.